{"id":"carbidopa-high-dose","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1200748","moleculeType":"Small molecule","molecularWeight":"244.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the enzyme aromatic L-amino acid decarboxylase, carbidopa increases the levels of levodopa in the brain, which is then converted to dopamine, a neurotransmitter that helps regulate movement and other functions.","oneSentence":"Carbidopa is a decarboxylase inhibitor that prevents the conversion of levodopa to dopamine, thereby increasing the availability of levodopa in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:49:04.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease"},{"name":"Dopa-responsive dystonia"}]},"trialDetails":[{"nctId":"NCT03197493","phase":"PHASE2","title":"Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Snyder, Robert W., M.D., Ph.D., P.C.","startDate":"2017-08-01","conditions":"Macula; Degeneration, Retina","enrollment":35},{"nctId":"NCT04520178","phase":"PHASE2, PHASE3","title":"Effects of 5HTP on the Injured Human Spinal Cord","status":"RECRUITING","sponsor":"University of Alberta","startDate":"2020-07-01","conditions":"Spinal Cord Injuries","enrollment":30},{"nctId":"NCT04735627","phase":"NA","title":"Real-Time Levodopa Level Monitoring in Parkinson Disease","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2021-12-07","conditions":"Parkinson Disease","enrollment":20},{"nctId":"NCT02096601","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients","status":"COMPLETED","sponsor":"NeuroDerm Ltd.","startDate":"2014-08-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT03781167","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-04-29","conditions":"Parkinson's Disease (PD)","enrollment":244},{"nctId":"NCT05976737","phase":"PHASE1","title":"Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects","status":"UNKNOWN","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2023-08-17","conditions":"Healthy","enrollment":68},{"nctId":"NCT03761030","phase":"PHASE4","title":"L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults","status":"TERMINATED","sponsor":"New York State Psychiatric Institute","startDate":"2019-01-09","conditions":"Major Depressive Disorder, Dysthymia, Depression","enrollment":51},{"nctId":"NCT02553265","phase":"PHASE2","title":"Carbidopa for the Treatment of Excessive Blood Pressure Variability","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2015-09","conditions":"Dysautonomia, Familial, Baroreflex Failure Syndrome","enrollment":22},{"nctId":"NCT01951105","phase":"PHASE4","title":"Effect of L-dopa In Subacute Back Pain Population","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-02-24","conditions":"Sub-acute Back Pain","enrollment":72},{"nctId":"NCT01399905","phase":"PHASE2","title":"High and Low Dose Carbidopa Treatment of Parkinson's Disease","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2009-03","conditions":"Parkinson's Disease","enrollment":14},{"nctId":"NCT02782481","phase":"PHASE3","title":"A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations","status":"WITHDRAWN","sponsor":"NeuroDerm Ltd.","startDate":"2016-08","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02706977","phase":"PHASE1","title":"The Effect of Dopamine on Diabetic Retinopathy","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-01","conditions":"Diabetes","enrollment":60},{"nctId":"NCT01393457","phase":"PHASE2","title":"Cognitive Remediation for Cocaine Dependence","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-06","conditions":"Cocaine Dependence","enrollment":119},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":"Hypertension","enrollment":152},{"nctId":"NCT01617135","phase":"PHASE2","title":"Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and \"Off\" Episodes","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2012-05","conditions":"Idiopathic Parkinson's Disease","enrollment":25},{"nctId":"NCT00218023","phase":"PHASE2","title":"Medications for Stopping Cocaine Dependence and Preventing Relapse","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2006-03","conditions":"Cocaine Abuse, Cocaine-Related Disorders","enrollment":101},{"nctId":"NCT02812394","phase":"PHASE1","title":"A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets","status":"COMPLETED","sponsor":"Acorda Therapeutics","startDate":"2016-06","conditions":"Parkinson Disease","enrollment":24},{"nctId":"NCT00789672","phase":"PHASE2","title":"Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2009-01","conditions":"Amblyopia","enrollment":33},{"nctId":"NCT00888186","phase":"PHASE4","title":"Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2008-02","conditions":"Parkinson Disease, Dyskinesias","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lodosyn ®, DL-α-methyl-α-hydrazino-3, 4-dihydroxyphenyl-propionic acid, HMD, MK-486"],"phase":"phase_2","status":"active","brandName":"Carbidopa High-Dose","genericName":"Carbidopa High-Dose","companyName":"NYU Langone Health","companyId":"nyu-langone-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carbidopa is a small molecule inhibitor of the enzyme aromatic-L-amino-acid decarboxylase, specifically acting as a DOPA decarboxylase inhibitor. It has been studied in various clinical trials, including those for conditions such as spinal cord injuries, amblyopia, and major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}